PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
ATHE Alterity Therapeutics
- 4.4200
- 0.00000.00%
Close Feb 14 16:00 ET
- 4.3800
- -0.0400-0.90%
Post 19:33 ET
38.64MMarket Cap-2.23P/E (TTM)
4.5000High4.2800Low58.88KVolume4.3800Open4.4200Pre Close261.46KTurnover0.76%Turnover RatioLossP/E (Static)8.74MShares5.870052wk High4.41P/B34.27MFloat Cap1.001052wk Low--Dividend TTM7.75MShs Float51.5000Historical High--Div YieldTTM4.98%Amplitude1.0010Historical Low4.4400Avg Price1Lot Size
Trending Stocks
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Alterity Therapeutics Stock Forum
Alterity's Game-Changing MSA Treatment Gets A$40M Boost After 48% Disease Slowdown Results
Alterity Therapeutics Raises A$40.0 million in Placement
February 10, 2025 Alterity Therapeutics
– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders –
– Capital raising was strongly supported by domestic and international institutional investors –
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 10 February 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or the “Company”), a biotechnology company dedicated to...
JPMorgan Chase & Co. and its affiliates have emerged as a substantial shareholder in Alterity Therapeutics, acquiring a 5.11% stake representing 272,198,215 ordinary shares as of February 3, 2025.
Between the news and trade halt, historic news release, expedited FDA approval track, and institutions buying in ...
something is cooking. predicting good news regarding FDA, so we're looking at a good ol pump.
watching close to determine target price. as of now I'm thi...
sharelinktechno...
c/o nowuuuah
No comment yet